rock inhibitors y-39983/snj-1656/rki-983 (Novartis)
90
Structured Review
Novartis
rock inhibitors y-39983/snj-1656/rki-983
Rock Inhibitors Y 39983/Snj 1656/Rki 983, supplied by Novartis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/y-39983/y+39983/pmc03104796-120-0-8
Average 90 stars, based on 1 article reviews
Rock Inhibitors Y 39983/Snj 1656/Rki 983, supplied by Novartis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/y-39983/y+39983/pmc03104796-120-0-8
Average 90 stars, based on 1 article reviews
rock inhibitors y-39983/snj-1656/rki-983 - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
Clinical Proteomics:Article Title: Rho kinase inhibitors: a patent review (2014 - 2016). Article Snippet: Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=ietp20 Download by: [The UC San Diego Library] Date: 05 January 2017, At: 01:40 Expert Opinion on Therapeutic Patents ISSN: 1354-3776 (Print) 1744-7674 (Online) Journal homepage: http://www.tandfonline.com/loi/ietp20 Rho kinase inhibitors: a patent review (2014 – 2016) Olivier Defert & Sandro Boland To cite this article: Olivier Defert & Sandro Boland (2017): Rho kinase inhibitors: a patent review (2014 – 2016), Expert Opinion on Therapeutic Patents, DOI: 10.1080/13543776.2017.1272579 To link to this article: http://dx.doi.org/10.1080/13543776.2017.1272579 Accepted author version posted online: 03 Jan 2017.. Submit your article to this journal View related articles View Crossmark data Publisher: Taylor & Francis Journal: Expert Opinion on Therapeutic Patents DOI: 10.1080/13543776.2017.1272579 Rho kinase inhibitors: a patent review (2014 – 2016) Olivier Defert† & Sandro Boland†,# †: Amakem Therapeutics NV, Agoralaan A Bis, 3590 Diepenbeek, Belgium #: current address: Cistim, Gaston Geenslaan 2, 3001 Leuven, Belgium Corresponding author: Olivier Defert, PhD, Amakem N.V. Agoralaan Abis, 3590 Diepenbeek.. Belgium. Article Title: Towards axonal regeneration and neuroprotection in glaucoma: Rho kinase inhibitors as promising therapeutics. Article Snippet: As a consequence, avoiding systemic exposure, recent development of ROCK inhibitors has been largely restricted to topical applications, e.g. clinical trials with Article Title: 3-[2-(Aminomethyl)-5-[(pyridin-4-yl)carbamoyl]phenyl] benzoates as soft ROCK inhibitors. Article Snippet: Contents lists available at ScienceDirect Bioorganic & Medicinal Chemistry Letters journal homepage: www.elsevier .com/ locate/bmcl 3-[2-(Aminomethyl)-5-[(pyridin-4-yl)carbamoyl]phenyl] benzoates as soft ROCK inhibitors 0960-894X/$ - see front matter 2013 Elsevier Ltd. All rights reserved. http://dx.doi.org/10.1016/j.bmcl.2013.09.040 ⇑ Corresponding author.. E-mail address: sandro.boland@amakem.com (S. Boland).. Sandro Boland a,⇑, Olivier Defert a, Jo Alen a, Arnaud Bourin a, Karolien Castermans a, Nele Kindt a, Nicki Boumans a, Laura Panitti a, Sarah Van de Velde b, Ingeborg Stalmans b, Dirk Leysen a a Amakem N.V. Agoralaan A bis, Diepenbeek 3590, Belgium b Laboratory of Ophthalmology, KU Leuven, Leuven 3000, Belgium a r t i c l e i n f o a b s t r a c t Article history: Received 12 August 2013 Revised 12 September 2013 Accepted 13 September 2013 Available online 21 September 2013 Keywords: Kinase inhibitor ROCK Soft drug SAR Esterase Clinical development of ROCK inhibitors has so far been limited by systemic or local ROCK-associated side effects. Article Title: Novel ocular antihypertensive compounds in clinical trials Article Snippet: Preclinical studies in monkeys showed 2.3 to 4.4 mm Hg decreases in Article Title: Discovery of novel inhibitors for the treatment of glaucoma Article Snippet: Y-39983 , Senju, Japan; and Article Title: Design, synthesis, and biological evaluation of novel, highly active soft ROCK inhibitors. Article Snippet: Subscriber access provided by NEW YORK UNIV Journal of Medicinal Chemistry is published by the American Chemical Society.. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society.. Copyright © American Chemical Society. Article Title: Novel ocular antihypertensive compounds in clinical trials Article Snippet: Full Display Name:Article Title: Rho kinase inhibitors: a patent review (2014 - 2016). Article Snippet: Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=ietp20 Download by: [The UC San Diego Library] Date: 05 January 2017, At: 01:40 Expert Opinion on Therapeutic Patents ISSN: 1354-3776 (Print) 1744-7674 (Online) Journal homepage: http://www.tandfonline.com/loi/ietp20 Rho kinase inhibitors: a patent review (2014 – 2016) Olivier Defert & Sandro Boland To cite this article: Olivier Defert & Sandro Boland (2017): Rho kinase inhibitors: a patent review (2014 – 2016), Expert Opinion on Therapeutic Patents, DOI: 10.1080/13543776.2017.1272579 To link to this article: http://dx.doi.org/10.1080/13543776.2017.1272579 Accepted author version posted online: 03 Jan 2017.. Submit your article to this journal View related articles View Crossmark data Publisher: Taylor & Francis Journal: Expert Opinion on Therapeutic Patents DOI: 10.1080/13543776.2017.1272579 Rho kinase inhibitors: a patent review (2014 – 2016) Olivier Defert† & Sandro Boland†,# †: Amakem Therapeutics NV, Agoralaan A Bis, 3590 Diepenbeek, Belgium #: current address: Cistim, Gaston Geenslaan 2, 3001 Leuven, Belgium Corresponding author: Olivier Defert, PhD, Amakem N.V. Agoralaan Abis, 3590 Diepenbeek.. Belgium. Article Title: Towards axonal regeneration and neuroprotection in glaucoma: Rho kinase inhibitors as promising therapeutics. Article Snippet: As a consequence, avoiding systemic exposure, recent development of ROCK inhibitors has been largely restricted to topical applications, e.g. clinical trials with Article Title: 3-[2-(Aminomethyl)-5-[(pyridin-4-yl)carbamoyl]phenyl] benzoates as soft ROCK inhibitors. Article Snippet: Contents lists available at ScienceDirect Bioorganic & Medicinal Chemistry Letters journal homepage: www.elsevier .com/ locate/bmcl 3-[2-(Aminomethyl)-5-[(pyridin-4-yl)carbamoyl]phenyl] benzoates as soft ROCK inhibitors 0960-894X/$ - see front matter 2013 Elsevier Ltd. All rights reserved. http://dx.doi.org/10.1016/j.bmcl.2013.09.040 ⇑ Corresponding author.. E-mail address: sandro.boland@amakem.com (S. Boland).. Sandro Boland a,⇑, Olivier Defert a, Jo Alen a, Arnaud Bourin a, Karolien Castermans a, Nele Kindt a, Nicki Boumans a, Laura Panitti a, Sarah Van de Velde b, Ingeborg Stalmans b, Dirk Leysen a a Amakem N.V. Agoralaan A bis, Diepenbeek 3590, Belgium b Laboratory of Ophthalmology, KU Leuven, Leuven 3000, Belgium a r t i c l e i n f o a b s t r a c t Article history: Received 12 August 2013 Revised 12 September 2013 Accepted 13 September 2013 Available online 21 September 2013 Keywords: Kinase inhibitor ROCK Soft drug SAR Esterase Clinical development of ROCK inhibitors has so far been limited by systemic or local ROCK-associated side effects. Article Title: Novel ocular antihypertensive compounds in clinical trials Article Snippet: Preclinical studies in monkeys showed 2.3 to 4.4 mm Hg decreases in Article Title: Discovery of novel inhibitors for the treatment of glaucoma Article Snippet: Y-39983 , Senju, Japan; and Article Title: Design, synthesis, and biological evaluation of novel, highly active soft ROCK inhibitors. Article Snippet: Subscriber access provided by NEW YORK UNIV Journal of Medicinal Chemistry is published by the American Chemical Society.. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society.. Copyright © American Chemical Society. Article Title: Novel ocular antihypertensive compounds in clinical trials Article Snippet: |
